EPCAM and neoplasm: According to clinicaltrials.gov, current clinical trials involve a study done in University Hospital Zurich, Switzerland for the use of magnetic NPs, coated with epithelial cell adhesion molecule (EpCAM)–antibodies to target epithelial tumor cells.